Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy.
BACKGROUND
Chronic pruritus is a global clinical problem with a high impact on the quality of life and lack of specific therapies. It is an excruciating and frequent symptom of e.g. uncurable renal, liver and skin diseases which often does not respond to conventional treatment with e.g. antihistamines. Therefore antipruritic therapies which target physiological mechanisms of pruritus need to be developed. Substance P (SP) is a major mediator of pruritus. As it binds to the neurokinin receptor 1 (NKR1), we evaluated if the application of a NKR1 antagonist would significantly decrease chronic pruritus.


RESULTS
Twenty hitherto untreatable patients with chronic pruritus (12 female, 8 male; mean age, 66.7 years) were treated with the NKR1 antagonist aprepitant 80 mg for one week. 16 of 20 patients (80%) experienced a considerable reduction of itch intensity, as assessed by the visual analog scale (VAS, range 0 to 10). Considering all patients, the mean value of pruritus intensity was significantly reduced from 8.4 VAS points (SD +/-1.7) before treatment to 4.9 VAS points (SD +/-3.2) (p<0.001, CI 1.913-5.187). Patients with dermatological diseases (e.g. atopic diathesis, prurigo nodularis) had the best profit from the treatment. Side-effects were mild (nausea, vertigo, and drowsiness) and only occurred in three patients.


CONCLUSIONS
The high response rate in patients with therapy refractory pruritus suggests that the NKR1 antagonist aprepitant may indeed exhibit antipruritic effects and may present a novel, effective treatment strategy based on pathophysiology of chronic pruritus. The results are promising enough to warrant confirming the efficacy of NKR1 antagonists in a randomized, controlled clinical trial.
Ständer
Sonja
S
Department of Dermatology, Neurodermatology and Competence Center Pruritus, University of Münster, Münster, Germany. sonja.staender@uni-muenster.de
Siepmann
Dorothee
D
Herrgott
Ilka
I
Sunderkötter
Cord
C
Luger
Thomas A
TA
D000368:Aged; D000369:Aged, 80 and over; D000077608:Aprepitant; D002908:Chronic Disease; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000494:pharmacology* / Q000627:therapeutic use; D011537:Pruritus / Q000188:drug therapy*; D018040:Receptors, Neurokinin-1 / Q000187:drug effects*; D016896:Treatment Outcome
D009025:Morpholines; D018040:Receptors, Neurokinin-1; D000077608:Aprepitant